Navigation Links
UMass Consortium awarded $300,000 from Juvenile Diabetes Research Foundation and Iacocca Foundation
Date:11/1/2007

WORCESTER, Mass.Investigators from the University of Massachusetts Medical School (UMMS) will investigate the causes of type 1 diabetes with dual grants from the Juvenile Diabetes Research Foundation (JDRF) and The Iacocca Foundation. The grants, of $150,000 each, will support the research efforts of the UMMS Heat Shock Protein Consortium. Directed by Aldo A. Rossini, MD, the William and Doris Krupp Professor of Medicine and professor of medicine and molecular medicine, the Heat Shock Protein Consortium brings together a unique group of scientists with diverse expertise in the basic sciences.

The innovation and synergy of the Consortium has already provided a mechanism for interaction and productivity in the field of science, explained Dr. Rossini. This synergy, we believe, will permit a new area of discovery by bringing together viewpoints of basic cell biology that are now focusing on the understanding of the pathogenesis of type 1 diabetes.

Heat shock proteins (Hsp) are essential proteins that protect the cell from a wide variety of environmental stresses. However, recent studies have demonstrated that altered Hsp function is associated with the development of a number of diseases, including type 1 diabetes. This funding will provide support for a number of innovative studies across a variety of departments and disciplines that aim to understand the Hsp abnormalities that may lead to the development and progression of type 1 diabetes.

We are committed to supporting young investigators in their development into diabetes-related careers and this important funding will foster creative approaches to the question of the role of cellular stress and autoimmune diabetes, explained Consortium investigator Dale L. Greiner, PhD, professor of medicine.

Better understanding the pathogenesis of diabetes will help accelerate the pace of science leading to cures and treatments for type 1 diabetes and its complications across a range of research areas, said Richard A. Insel, MD, Executive Vice President for Research at JDRF. Were thrilled to be partnering with The Iacocca Foundation to fund this important science at the University of Massachusetts Medical School.

Specific laboratories and their respective projects supported by the grants include:

  • Rita Bortell, PhD, associate professor of medicineThe role of endoplasmic reticulum (ER) stress in immune cell functions and during pathogenesis of autoimmune diabetes
  • Stephen J. Doxsey, PhD, professor of molecular medicine, biochemistry & molecular pharmacology and cell biologyThe novel role of centrosome proteins in insulin secretion and cellular stress
  • Dale L. Greiner, PhD, professor of medicineThe role of ER stress in islet transplantation
  • Gregory J. Pazour, PhD, associate professor of molecular medicineThe role of the pancreatic beta cell cilium in diabetes
  • Fumihiko Urano, MD, assistant professor of molecular medicineThe role of ER stress in autoimmune diabetes

Were excited about this partnership, said Iaccoca Foundation Executive Director Dana Ball. Our mission is to explore every possible avenue to find a cure for type 1 diabetes and we see incredible promise in the innovative approach UMass is taking.


'/>"/>

Contact: Kelly Bishop
kelly.bishop@umassmed.edu
508-856-2000
University of Massachusetts Medical School
Source:Eurekalert

Related medicine news :

1. Chancellor Of UMass Medical School Resigns Due to Health Reasons
2. NIH Funds the Development of National Consortium of Universities
3. Autism Gene Identified by Yale and Global Consortium
4. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
5. Scientists Awarded Appropriately For Contribution Towards Medical Research
6. Lifespan And Height Interlinked With Juvenile Diseases.
7. Psychiatric disorders among juveniles
8. Migraine & Juvenile stroke could be associated
9. Guidelines for treatment of juvenile idiopathic arthritis formulated
10. Type I diabetes or juvenile diabetes delays kidney disease onset
11. A New Technique For Treating Juvenile Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016 aTyr Pharma, Inc. (Nasdaq: ... development of Physiocrine-based therapeutics to address severe, rare diseases, today announced ... upcoming BMO Prescriptions for Success Healthcare Conference at the InterContinental Barclay ... December 14, 2016, at 4:20 p.m. ET. About ... ...
(Date:12/9/2016)... , Dec. 9, 2016 Department of Health ... regulations for medical marijuana dispensaries under Act 16 are ... , and are now available online . ... in the plan for operation; process for dispensing medical ... well as where the dispensary facilities can be located," ...
(Date:12/8/2016)... VIEW, Calif. , Dec. 8, 2016 IRIDEX ... intends to offer newly issued shares of common stock, $0.01 ... pursuant to an underwritten public offering.  The final terms of ... the time of pricing, and there can be no assurance ... IRIDEX expects to use the net proceeds it ...
Breaking Medicine Technology: